Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA.
P1462: POPULATION‐BASED REAL WORLD RESULTS OF CD19‐DIRECTED CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA: A DUTCH CAR T‐CELL TUMORBOARD EXPERIENCE.
S211: CLINICAL AND PATIENT‐REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (ZUMA‐7)
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Autorzy:
Spanjaart AM; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands. Pennings ERA; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, 3062 PA Rotterdam, The Netherlands. Mutsaers PGNJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. van Dorp S; Department of Hematology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands. Jak M; Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands. van Doesum JA; Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. de Boer JW; Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Niezink AGH; Department of Radiation Oncology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Kos M; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, 1081 HV Amsterdam, The Netherlands. Vermaat JSP; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Sijs-Szabo A; Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. van der Poel MWM; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands. Nijhof IS; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.; Department of Internal Medicine-Hematology, St Antonius Hospital, 3435 CM Nieuwegein, The Netherlands. Kuipers MT; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands. Chamuleau MED; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Hematology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands. Lugtenburg PJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Doorduijn JK; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Serroukh YIM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands. Minnema MC; Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands. Kersten MJ; Department of Hematology, Amsterdam UMC Location University of Amsterdam, 1007 MB Amsterdam, The Netherlands.; Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands.; LYMMCARE (Lymphoma and Myeloma Center Amsterdam), 1105 AZ Amsterdam, The Netherlands.
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Autorzy:
Bouwstra R; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. vanMeertenT; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Bremer E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
